Long-term safety and effectiveness of rozanolixizumab for ocular myasthenia gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study is a long-term follow-up to see if the treatment from the previous study continues to be safe and effective for people with ocular myasthenia gravis (a condition causing muscle weakness in the eyes). It involves continuing or monitoring the effects of the drug rozanolixizumab.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have participated in the earlier MG0038 study and received at least one dose of the study drug or placebo.
- You must not have an active infection that required hospitalization or IV antibiotics within the last 6 weeks.
- You must agree not to receive live vaccines during the study and for 8 weeks after the last dose.
- You must agree not to use any prohibited immunosuppressive medications during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational medication called rozanolixizumab for people who have ocular myasthenia gravis (MG), where weakness is only in the eye muscles. The medicine is given as an injection under the skin and may help improve symptoms like drooping eyelids or double vision.
This trial tests whether a combination of steroid medicine (corticosteroid) and a targeted immune drug (rituximab) can prevent mild eye-muscle weakness from spreading to other muscles. It is for people newly diagnosed with ocular myasthenia who have not yet taken immune-suppressing treatments.
This real-world study looks at how different immunosuppressant medicines work for people with non-thymoma ocular myasthenia gravis (eye symptoms due to MG). It may help doctors understand which treatments control symptoms best in everyday care.
This study continues treatment for children who took part in an earlier trial (MG0006) for generalized myasthenia gravis. It tests 6-week cycles of a drug called rozanolixizumab to see if it continues to work well and stay safe.
This study follows patients with generalized myasthenia gravis (a condition where muscles weaken over time) who have specific antibodies and are being treated with rozanolixizumab, a medication that helps reduce symptom severity. Researchers will monitor how symptoms change in real-world settings.
This study tests an investigational drug called rozanolixizumab for Chinese adults with generalized myasthenia gravis who have a specific antibody (AChR or MuSK) and symptoms that still affect daily activities. It aims to see if the drug helps improve muscle strength and quality of life.
Hear when a new Ocular Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.